Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma
- 25 June 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 37 (6) , 599-609
Abstract
Background. Localized scleroderma (LS) is a disfiguring inflammatory autoimmune disease of the skin and underlying tissue. As in systemic sclerosis, a key feature is the presence of T cells in inflammatory lesions. Aim. To evaluate the effect of polymerized type I collagen vs. methylprednisolone (MP) in LS, and to determine the influence of this polymerized collagen (PC) on CD4+ peripheral T cells expressing interleukin (IL)‐4, IL‐17A, interferon‐γ and Forkhead box protein (Foxp)3, and on cells expressing transforming growth factor (TGF)‐β1, IL‐17A, IL‐22 and Foxp3 in the skin. Methods. In total, 16 patients with LS were treated for 3 months with monthly subcutaneous intralesional injections of 0.1 mL MP (giving a total dose of 20 mg/mL each month) and 15 patients were treated, with weekly subcutaneous intralesional injections of PC, ranging from 0.2 mL (equivalent to 1.66 mg collagen) for a lesion of 50 mm in size, up to a maximum of 1.0 mL (8.3 mg collagen) for a lesion > 100 mm in size, and followed up for a further 6 months. Skin biopsies were obtained from lesions at baseline (before treatment) and 9 months later (6 months after treatment end). Tissue sections were evaluated by histology and immunohistochemistry (IL‐17A, IL‐22, TGF‐β1 and Foxp3). CD4+ T‐cell subsets were determined in peripheral blood by flow cytometry. Results. Abnormal tissue architecture was seen in the biopsies taken from patients treated with MP, whereas the PC treatment restored normal skin architecture. PC downregulated pro‐inflammatory/profibrotic cytokine expression in peripheral cells, and upregulated the number of regulatory T cells (Tregs) in skin. PC was safe and well tolerated. Conclusions. PC is not only an antifibrotic/fibrolytic agent but also an immunomodulator biodrug that restores the balance between T helper (Th)1, Th2, Th17 and Tregs, downregulates production of pro‐inflammatory or profibrogenic cytokines (IL‐17A, IL‐22 and TGF‐β1), and renews skin architecture, without adverse effects.Keywords
This publication has 22 references indexed in Scilit:
- Cytokine profiles in localized scleroderma and relationship to clinical featuresCytokine, 2011
- Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional studyRheumatology International, 2011
- Circulating Th17, Th22, and Th1 Cells Are Increased in PsoriasisJournal of Investigative Dermatology, 2010
- Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 productionProceedings of the National Academy of Sciences, 2009
- Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cellsNature Immunology, 2009
- Human Th17 cells: Are they different from murine Th17 cells?European Journal of Immunology, 2009
- Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosisRheumatology, 2008
- T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγImmunity, 2008
- Localized scleroderma is an autoimmune disorderRheumatology, 2005
- IL-22 Increases the Innate Immunity of TissuesImmunity, 2004